Clinical trials: Anxious-Depressive
Depressive Symptoms, Anxiety Disorders
Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study
Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness…
- Trial name
- NCT03699488
- Testing
- psychotherapy via asynchronous message
- Volunteers
- 12,980 people
- Sponsor
- Talkspace
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Depressive Disorder and Anxiety Disorders
A First Time in Human Study of GSK586529 in Healthy Volunteers
A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male subjects. Subjects will be divided into two cohorts with alternate panel design.
- Trial name
- NCT00703547
- Testing
- GSK586529 capsules, GSK586529 tablets
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.
- Trial name
- NCT07161700
- Testing
- SPT-300
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Depressive Disorder, Anxiety Disorder
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety…
- Trial name
- NCT01491035
- Testing
- Vortioxetine
- Where
- 7 sites in United States, Germany
- Volunteers
- 48 people
- Sponsor
- H. Lundbeck A/S
Depression - Major Depressive Disorder, Anxiety
Validation of Accexible Screening and Self-Administered Activities for Emotional Well-Being in a University Hospital (UaDEC)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07578155
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 902 people, healthy volunteers welcome
- Sponsor
- Accexible
Schizophrenia, Drug Abuse
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
The prevalence estimates for specific mental disorders and illicit drugs have been separately reported in U.S. government surveys.
- Conditions
- Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder
- Trial name
- NCT02476877
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Advanced Clinical Laboratory Solutions, Inc.
Depressive Disorder, Major
A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom
The purpose of this study is to evaluate the impact of escitalopram on quality of life and social functionality in patients with major depressive disorder with anxiety symptom.
- Trial name
- NCT01870843
- Testing
- Escitalopram
- Where
- 10 sites in China
- Volunteers
- 261 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
PTSD, Anxiety
Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids
The primary objective of this study is to collect insights from first responders and military personnel on their need for, use of, and interest in physical and/or mental health medical marijuana or psychedelic-assisted therapy…
- Conditions
- PTSD, Anxiety, Anxiety Disorders, Depression
- Trial name
- EMPOWER (NCT04965740)
- Testing
- Cannabis
- Where
- Canada
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Empower Research Inc
Depressive Disorder and Anxiety Disorders
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
The study will consist of a screening period, 3 treatment periods and a post-treatment follow-up. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a…
- Trial name
- NCT00536679
- Testing
- GSK163090 capsule, fasted, GSK163090 Tablet, fasted, GSK163090 Tablet, fed
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder and Anxiety Disorders
First Time in Human Study
This study will evaluate the safety, tolerability, and pharmacokinetics of GSK356278 in male volunteers
- Trial name
- FTIM (NCT01031186)
- Testing
- GSK356278
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Anxiety
Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety
The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.
- Trial name
- NCT00621270
- Testing
- BCI-540
- Where
- 16 sites in Canada
- Volunteers
- 115 people
- Sponsor
- BrainCells Inc.
Major Depressive Disorder, Generalized Anxiety Disorder
Digital Therapeutic for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)
Participants with Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) will use a prescribed digital therapeutic for 8-10 weeks, and will complete depression and anxiety measures during this time.
- Trial name
- NCT05016050
- Testing
- HPDT-DA-013
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Happify Inc.
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT02196506
- Testing
- Brexpiprazole +ADT
- Where
- 47 sites in United States, Germany and 3 more
- Volunteers
- 837 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Symptoms
EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY
This study is planned to assess the efficacy of SAMEUp versus placebo after six weeks of treatment in subjects characterized by depression symptoms according to ICD-10 (International Classification of Diseases - 10th revision)…
- Trial name
- SAMEUP (NCT03932474)
- Testing
- SAMEUp
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Nutrilinea srl
Major Depressive Disorder, Anxiety
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate…
- Trial name
- NCT02013531
- Testing
- Brexpiprazole
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.